natgillin/translations-raw huggingface dataset:
Der var ingen akkumulering af tipiracilhydrochlorid og ingen yderligere akkumulering af trifluridin ved successive cykler (dag 12 i cyklus 2 og 3) efter administration af Lonsurf.
However, there was no accumulation for tipiracil hydrochloride, and no further accumulation of trifluridine with successive cycles (Day 12 of Cycles 2 and 3) of administration of Lonsurf.
OS var mere favorabel i gruppen med høj AUC sammenlignet med gruppen med lav AUC (median OS på henholdsvis 9,3 og 8,1 måneder).
OS appeared more favourable in the high AUC group compared to the low AUC group (median OS of 9.3 vs. 8.1 months, respectively).
• protein i urinen
• protein in your urine
Baseret på resultater fra dyr kan trifluridin forårsage fosterskader ved administration til gravide kvinder.
Based on findings in animals, trifluridine may cause foetal harm when administered to pregnant women.
Dosis beregnes ud fra kroppens overfladeareal (body surface area, BSA) (se tabel 1).
The dosage is calculated according to body surface area (BSA) (see Table 1).
18 % (N = 144) af alle randomiserede patienter fik regorafenib før randomiseringen.
Eighteen percent (18%, N = 144) of all randomised patients received regorafenib prior to randomisation.
Alle, bortset fra 1 patient, fik bevacizumab, og alle, bortset fra 2 patienter med KRAS-vildtype-tumorer fik panitumumab eller cetuximab.
All but 1 patient received bevacizumab, and all but 2 patients with KRAS wild type tumours received panitumumab or cetuximab.
De primære cancerformer var gastrisk cancer (71,0 %), cancer i den gastroøsofageale overgang (28,6 %) eller begge (0,4 %).
Primary cancer was gastric (71.0%) or gastroesophageal junction cancer (28.6%) or both (0.4%).
I tilfælde af hæmatologisk og/eller ikke-hæmatologisk toksicitet skal patienten følge kriterierne for doseringsafbrydelse, doseringsgenoptagelse og dosisreduktion i tabel 2, tabel 3 og tabel 4.
In the event of haematological and/or non-haematological toxicities patients should follow the dose interruption, resumption and reduction criteria stated in Table 2, Table 3 and Table 4.
Patienterne fortsatte behandlingen indtil sygdomsprogression eller uacceptabel toksicitet (se pkt.
Patients continued therapy until disease progression or unacceptable toxicity (see section
Symptomerne inkluderer kulderystelser, feber, sveden eller andre tegn på bakterie- eller svampeinfektion (se punkt 2).
The signs include chills, fever, sweating or other sign of bacterial or fungal infection (see section 2).
Der er ikke udført langtidsstudier, som evaluerer det karcinogene potentiale af trifluridin/tipiracilhydrochlorid hos dyr.
No long term studies evaluating the carcinogenic potential of trifluridine/tipiracil hydrochloride in animals have been performed.
LISTE OVER HJÆLPESTOFFER Indeholder lactosemonohydrat, se indlægssedlen for yderligere information.
LIST OF EXCIPIENTS Contains lactose monohydrate, see leaflet for further information.
• CTCAE* grad 3 eller grad 4 ikkehæmatologisk bivirkning med undtagelse af grad 3 kvalme og/eller opkastning, som kontrolleres med antiemetisk behandling, og diarré, som reagerer på anti-diarré-lægemidler
• CTCAE* non-haematologic Grade 3 or Grade 4 adverse reaction; except for Grade 3 nausea and/or vomiting controlled by antiemetic therapy or diarrhoea responsive to antidiarrhoeal medicinal products
Mediantallet af tidligere behandlingsregimer for metastatisk sygdom var 3.
The median number of prior regimens of therapy for metastatic disease was 3.
Da størstedelen blev rapporteret i forbindelse med knoglemarvssuppression, skal patientens tilstand overvåges nøje, og passende behandling, såsom antimikrobielle midler og granulocyt-kolonistimulerende faktor (G-CSF), skal administreres som klinisk indiceret.
Given that the majority were reported in the context of bone marrow suppression, the patient's condition should be monitored closely, and appropriate measures, such as antimicrobial agents and granulocyte-colony stimulating factor (G-CSF), should be administered as clinically indicated.
• øget antal af de hvide blodlegemer, som kaldes monocytter
• increased number of white blood cells called monocytes
Forekomsten af alvorlige, svære bivirkninger og bivirkninger, som medfører dosismodifikation, har tendens til at øges i takt med stigende niveauer af nedsat nyrefunktion.
However, the incidence of serious, severe AEs and AEs leading to dose modification tends to increase with advancing levels of renal impairment.
Alle ændringer, dvs. leukopeni, anæmi, knoglemarvshypoplasi, atrofiske forandringer i lymfatiske og hæmatopoietiske væv og mave-tarm-kanalen, var reversible inden for 9 uger efter seponering.
All changes, i.e., leukopenia, anaemia, bone marrow hypoplasia, atrophic changes in the lymphatic and haematopoietic tissues and the gastrointestinal tract, were reversible within 9 weeks of drug withdrawal.
Der er ikke udført peri- eller postnatale studier af udviklingstoksicitet.
No peri/post-natal developmental toxicity studies have been performed.
Sandsynlighed for progressionsfri overlevelse (%)
Progression-free Survival Probability (%)
4.8, hvordan bivirkninger indberettes.
See Section 4.8 for how to report adverse reactions.
Maksimalt 3 dosisreduktioner er tilladt til en minimumdosis på 20 mg/m to gange dagligt.
A maximum of 3 dose reductions are permitted to a minimum dose of 20 mg/m2 twice daily.
Dysgeusi Perifer neuropati
Dysgeusia Neuropathy peripheral
Ved lave albuminværdier, i intervallet 2,2 til 3,5 g/dl, var de tilsvarende clearanceværdier fra 4,2 til 3,1 l/time.
For low albumin values ranging from 2.2 to 3.5 g/dL, the corresponding clearance values range from 4.2 to 3.1 L/h.
Hvidfarvning, brud og malokklusion blev observeret i tænderne hos rotter behandlet med trifluridin/ tipiracilhydrochlorid, men dette anses for gnaverspecifikt og ikke relevant for mennesker.
Whitening, breakage, and malocclusion were observed in teeth of rats treated with trifluridine/tipiracil hydrochloride, which are considered rodent specific and not relevant for human.
Behandlingen i studiet blev administreret oralt 2 gange dagligt, efter morgen- og aftenmåltiderne, med 5 dages behandling og 2 dages pause i 2 uger, efterfulgt af 14 dages pause og gentaget hver 4. uge.
Study treatment was administered orally twice daily after morning and evening meals for 5 days a week with 2 days rest for 2 weeks, followed by 14 days rest, repeated every 4 weeks.
• blodprøveresultat, der tyder på inflammation (betændelseslignende reaktion) (øget niveau af Creaktivt protein)
• blood test result indicating inflammation (C-Reactive Protein increased)
Lonsurfs virkning og sikkerhed ved metastatisk kolorektal cancer blev sammenlignet mellem en højeksponerings-gruppe (> median) og en laveksponerings-gruppe (≤ median) baseret på median-AUC for trifluridin.
The efficacy and safety of Lonsurf in metastatic colorectal cancer was compared between a high exposure group (>median) and a low-exposure group (≤median) based on the median AUC value of trifluridine.
DCR (komplet respons, partielt respons eller stabil sygdom) var signifikant højere hos patienter, som blev behandlet med Lonsurf (44 % versus 16 %, p < 0,0001).
The DCR (complete response or partial response or stable disease) was significantly higher in patients treated with Lonsurf (44% vs 16%, p < 0.0001).
Alle patienter havde tidligere fået behandling med fluorpyrimidin-, oxaliplatin- og irinotecan-baseret kemoterapi.
All patients received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Tipiracilhydrochlorid var den vigtigste komponent og 6-hydroxymethyluracil var hovedmetabolitten i humant plasma, urin og fæces.
Tipiracil hydrochloride was the major component and 6-hydroxymethyluracil was the major metabolite consistently in human plasma, urine, and faeces.
Hvis du ikke er sikker, så tal med din læge, før du tager Lonsurf.
If you are not sure, talk to your doctor before taking Lonsurf.
Nedsat total-protein
Protein total decreased
Brug ikke lægemidlet efter den udløbsdato, der står på den ydre pakning eller blisterpakningen efter ”EXP”.
Do not use this medicine after the expiry date which is stated on the outer carton or blister tray after “EXP.” The expiry date refers to the last day of that month.
Kvinder i den fertile alder/Prævention til mænd og kvinder
Women of childbearing potential / Contraception in males and females
Dette skyldes, at Lonsurf kan påvirke den måde, anden medicin virker på, og ligeledes kan visse andre lægemidler påvirke den måde, Lonsurf virker på.
This is because Lonsurf can affect the way some other medicines work.
• Betændelseslignende reaktioner i lungerne er indberettet hos patienter, der får denne medicin.
• Interstitial lung disease has been reported in patients receiving the medicine.
I ikke-kliniske studier demonstrerede trifluridin/tipiracilhydrochlorid antitumoraktivitet overfor både 5-fluoruracil (5-FU) følsomme og resistente kolorektal cancer-cellelinjer.
In nonclinical studies, trifluridine/tipiracil hydrochloride demonstrated antitumour activity against both 5-fluorouracil (5-FU) sensitive and resistant colorectal cancer cell lines.
Den cytotoksiske aktivitet af trifluridin/tipiracilhydrochlorid mod adskillige humane tumorxenotransplantater korrelerede stærkt med mængden af trifluridin inkorporeret i DNA, hvilket antyder, at dette er den primære virkningsmekanisme.
The cytotoxic activity of trifluridine/tipiracil hydrochloride against several human tumour xenografts correlated highly with the amount of trifluridine incorporated into DNA, suggesting this as the primary mechanism of action.
Det var ikke muligt at undersøge indflydelsen af gastrektomi på de farmakokinetiske parametre i en farmakokinetisk populationsanalyse, fordi der kun var få patienter, som havde undergået gastrektomi (1 % af den samlede population).
The influence of gastrectomy on PK parameters was not able to be examined in the population PK analysis because there were few patients who had undergone gastrectomy (1% of overall).
Forsigtighed er påkrævet ved brug sammen med lægemidler, som er substrater for human thymidinkinase, f.eks. zidovudin.
Caution is required when using medicinal products that are human thymidine kinase substrates, e.g., zidovudine.
Følelse af forandret kropstemperatur Xerose
Feeling of body temperature change Xerosis
• Aktive stoffer: Trifluridin og tipiracil.
• The active substances are trifluridine and tipiracil.
Når der anvendes antivirale lægemidler, som er substrater for human thymidinkinase, skal der derfor monitoreres for muligt nedsat effekt af det antivirale lægemiddel, og det bør overvejes at skifte til et andet antiviralt lægemiddel, der ikke er et substrat for human thymidinkinase, som f.eks. lamivudin, didanosin og abacavir (se pkt.
Therefore, when using antiviral medicinal products that are human thymidine kinase substrates, monitor for possible decreased efficacy of the antiviral medicinal product, and consider switching to an alternative antiviral medicinal product that is not a human thymidine kinase substrate, such as lamivudine, didanosine and abacavir (see section 5.1).
Tabel 2 - Kriterier for doseringsafbrydelse og doseringsgenoptagelse ved hæmatologisk toksicitet relateret til myelosuppression
Table 2 - Dose interruption and resumption criteria for haematological toxicities related to myelosuppression
Det er vist, at Lonsurf kan forårsage embryoføtal død og embryoføtal toksicitet hos drægtige rotter, når det blev givet ved dosisniveauer lavere end svarende til klinisk eksponering.
Lonsurf has been shown to cause embryo-foetal lethality and embryo-foetal toxicity in pregnant rats when given at dose levels lower than the clinical exposure.
Forlænget aktiveret partiel tromboplastintid
Activated partial thromboplastin time prolonged
De bivirkninger, der blev observeret hos 533 behandlede patienter med metastatisk kolorektal cancer i det placebokontrollerede kliniske fase III-studie (RECOURSE) og hos 335 behandlede patienter med metastatisk gastrisk cancer i det placebokontrollerede kliniske fase III-studie (TAGS), er vist i tabel 5.
The adverse drug reactions observed from the 533 treated patients with metastatic colorectal cancer in the placebo-controlled Phase III (RECOURSE) clinical trial and the 335 treated patients with metastatic gastric cancer in the placebo-controlled Phase III (TAGS) clinical trial, are shown in Table 5.
• helvedesild (smerte og udslæt med små blærer på huden over nervebanerne på grund nervebetændelse forårsaget af herpes zoster virus)
• shingles (pain and vesicular rash on skin over nerve tracts affected by nerve inflammation from herpes zoster virus)
Patienter med kvalme, opkastning, diarré og andre gastrointestinale bivirkninger skal overvåges nøje, og antiemetisk, anti-diarré og andre foranstaltninger, såsom væske/elektrolyt-substitutionsbehandling skal administreres som klinisk indiceret.
Patients with nausea, vomiting, diarrhoea and other gastrointestinal toxicities should be carefully monitored, and anti-emetic, anti-diarrhoeal and other measures, such as fluid/electrolyte replacement therapy, should be administered as clinically indicated.
Lonsurf anvendes til at behandle voksne med tyktarms- eller endetarmskræft - sommetider kaldet "kolorektal kræft” og mavekræft (herunder kræft i overgangen mellem spiserøret og mavesækken).
Lonsurf is used to treat adults with colon or rectal cancer - sometimes called ‘colorectal' cancer and stomach cancer (including cancer of the junction between the oesophagus and the stomach).
Det er vist, at trifluridin er genotoksisk i en revers mutationstest i bakterier, en kromosomaberrationstest i dyrkede pattedyrsceller og en mikronukleustest i mus.
Trifluridine was shown to be genotoxic in a reverse mutation test in bacteria, a chromosomal aberration test in mammal-cultured cells, and a micronucleus test in mice.
Laboratorieprøver og kontrol
Tests and checks
Mediantallet af førstelinjebehandlinger af metastatisk sygdom var 3.
The median number of prior lines of therapy for metastatic disease was 3.
Tabletter pr. dosis (2 × dagligt)
Tablets per dose (2x daily)
Meget almindelig: Kan forekomme hos flere end 1 ud af 10 personer
Very common: may affect more than 1 in 10 people:
Trifluridin blev hovedsageligt elimineret ved metabolisme via TPase ved dannelse af den inaktive metabolit FTY.
Trifluridine was mainly eliminated by metabolism via TPase to form an inactive metabolite, FTY.
Symptomerne inkluderer intense mavesmerter, som kan være forbundet med opkastning, blokeret eller delvist blokeret tarm, feber eller opsvulmning af maven.
The signs include intense stomach or abdominal pain that can be associated with vomiting, blocked or partly blocked bowel, fever or swelling of the abdomen.
C.A. Papaellinas Ltd. Τηλ: +357 22741741
Papaellinas Ltd. Τηλ: +357 22741741
Neutrofiler
Neutrophils
Stigningerne i antal corpora lutea og implanterede embryoner, observeret i hunrotter ved høje doser, blev ikke anset som en negativ virkning (se pkt.4.6).
The increases in the corpus luteum count and implanting embryo count observed in female rats at high doses were not considered adverse (see section 4.6).
Kvinder i den fertile alder skal derfor bruge meget effektive præventionsmidler, mens de tager Lonsurf og i 6 måneder efter, behandlingen er stoppet.
Therefore, women of child-bearing potential must use highly effective contraceptive measures while taking Lonsurf and for 6 months after stopping treatment.
Efter optagelse i cancerceller fosforyleres trifluridin af thymidinkinase, som intracellulært metaboliseres yderligere til et deoxyribonukleinsyre (DNA)-substrat og inkorporeres direkte i DNA og dermed interfererer med DNA-funktionen og hindrer celleproliferation.
Following uptake into cancer cells, trifluridine, is phosphorylated by thymidine kinase, further metabolised in cells to a deoxyribonucleic acid DNA substrate, and incorporated directly into DNA, thereby interfering with DNA function to prevent cell proliferation.
Symptomerne inkluderer usædvanlige blå mærker eller blødning (se punkt 2).
The signs include unusual bruising or bleeding (see section 2).
• ondt i halsen, hæs stemme, problemer med din stemme
• sore throat, hoarse voice, problems with your voice
Der er rapporteret alvorlige infektioner efter behandling med Lonsurf (se pkt.
Serious infections have been reported following treatment with Lonsurf (see section 4.8).
Amning bør afbrydes under behandling med Lonsurf.
Breast-feeding should be discontinued during treatment with Lonsurf.
• følelse af, at alting snurrer rundt (vertigo)
• feeling of spinning (vertigo)
Det gennemsnitlige relative forhold mellem AUC hos patienter med let (n = 38) og moderat (n = 16) nedsat nyrefunktion sammenlignet med patienter med normal nyrefunktion (n = 84) var henholdsvis 1,31 og 1,43 for trifluridin og 1,34 og 1,65 for tipiracilhydrochlorid.
The mean relative ratio of AUC in patients with mild (n=38) and moderate (n=16) renal impairment compared to patients with normal renal function (n=84) were 1.31 and 1.43 for trifluridine, respectively, and 1.34 and 1.65 for tipiracil hydrochloride, respectively.
En højere eksponering af Lonsurf blev observeret ved moderat nedsat nyrefunktion (CrCl = 30 til 59 ml /min).
A higher exposure of Lonsurf was observed in moderate renal impairment (CrCl = 30 to 59 mL/min).
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/16/1096/001-006
MARKETING AUTHORISATION NUMBER(S) EU/1/16/1096/001-006
Lonsurfs kliniske effekt og sikkerhed blev evalueret i et internationalt, randomiseret, dobbeltblindt placebo-kontrolleret fase III-studie (RECOURSE) hos patienter, som tidligere var behandlet for metastatisk kolorektal cancer.
The clinical efficacy and safety of Lonsurf were evaluated in an international, randomised, doubleblind, placebo-controlled Phase III study (RECOURSE) in patients with previously treated metastatic colorectal cancer.
• Hvis du har glemt at tage en dosis, skal du tale med din læge eller apotekspersonalet.
• If you forget a dose, talk to your doctor or pharmacist.
Trifluridin nedbrydes imidlertid hurtigt af TPase og metaboliseres hurtigt efter oral administration ved en first-pass effekt, hvorfor TPase-hæmmeren, tipiracilhydrochlorid, er tilsat.
However, trifluridine is rapidly degraded by TPase and readily metabolised by a first-pass effect following oral administration, hence the inclusion of the TPase inhibitor, tipiracil hydrochloride.
Det er derfor ikke sandsynligt, at det i de anbefalede doser forårsager interaktion med andre lægemidler på grund af hæmning af OCT2 eller MATE1.
Thus it is unlikely to cause an interaction with other medicinal products, at recommended doses, due to inhibition of OCT2 and MATE1.
Lonsurf forårsagede en stigning i forekomsten af gastrointestinal toksicitet, herunder kvalme, opkastning og diarré.
Lonsurf caused an increase in the incidence of gastrointestinal toxicities including nausea, vomiting and diarrhoea.
• øget niveau af lactatdehydrogenase i blodet
• increased lactate dehydrogenase level in your blood
Menstruationsforstyrrelser
Menstrual disorder
Baseret på en farmakokinetisk populationsanalyse var leverfunktionsparametrene, herunder alkalisk fosfatase (ALP, 36-2.322 E/l), aspartataminotransferase (ASAT, 11-197 E/l), alaninaminotransferase (ALAT, 5-182 E/ l) og total-bilirubin (0,17-3,20 mg /dl), ikke signifikante kovariater for de farmakokinetiske parametre hverken for trifluridin eller tipiracilhydrochlorid.
Based on the population PK analysis, liver function parameters including alkaline phosphatase (ALP, 36-2322 U/L), aspartate aminotransferase (AST, 11-197 U/L), alanine aminotransferase (ALT, 5-182 U/L) , and total bilirubin (0.17-3.20 mg/dL) were not significant covariates for PK parameters of either trifluridine or tipiracil hydrochloride.
• lavt indhold af fosfater, natrium, kalium eller calcium i blodet
• low levels of phosphates, sodium, potassium or calcium in your blood
I de kliniske fase III-studier forekom behandlingsrelaterede infektioner oftere hos Lonsurf-behandlede patienter (5,8 %) end hos patienter i placebo-gruppen (1,8 %).
In the Phase III clinical trials, treatment-related infections occurred more frequently in Lonsurf-treated patients (5.8%) compared to those receiving placebo (1.8%).
Den anbefalede startdosis af Lonsurf hos voksne er 35 mg/m dagligt på dag 1 til 5 og dag 8 til 12 i hver 28-dages-cyklus, så længe der observeres behandlingsmæssige fordele eller indtil uacceptabel toksicitet (se pkt.
The recommended starting dose of Lonsurf in adults is 35 mg/m2/dose administered orally twice daily on Days 1 to 5 and Days 8 to 12 of each 28-day cycle as long as benefit is observed or until unacceptable toxicity occurs (see section 4.4).
Urinvejsinfektion Gingivitis
Urinary tract infection Gingivitis
• synsproblemer som sløret syn, dobbeltsyn, nedsat syn, grå stær
• vision troubles as blurred vision, double vision, decreased vision, cataracts
De gennemsnitlige halveringstider af tipiracilhydrochlorid på henholdsvis dag 1 og dag 12 i cyklus 1 var 2,1 timer og 2,4 timer.
The mean t1/2 values for tipiracil hydrochloride on Day 1 of Cycle 1 and on Day 12 of Cycle 1 were 2.1 hours and 2.4 hours, respectively.
Tabel 1 - Beregning af startdosis ud fra kroppens overfladeareal (BSA)
Table 1 - Starting dose calculation according to body surface area (BSA)
• smerte eller ubehag i dine arme eller ben
• pain or discomfort in your arms or legs
Dosis i mg (2x dagligt)
Dose in mg (2x daily)
61 % (N = 485) af alle randomiserede patienter fik fluorpyrimidin, som en del af deres sidste behandlingsregime før randomisering, hvor (94 %) var refraktære overfor fluorpyrimidin på dette tidspunkt.
Sixty one percent (61%, N = 485) of all randomised patients received a fluoropyrimidine as part of their last treatment regimen prior to randomisation, of which 455 (94%) were refractory to the fluoropyrimidine at that time.
Det Europæiske lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med Lonsurf i alle undergrupper af den pædiatriske population ved refraktær metastatisk kolorektal cancer og ved refraktær metastatisk gastrisk cancer (se pkt.
The European Medicines Agency has waived the obligation to submit the results of studies with Lonsurf in all subsets of the paediatric population in refractory metastatic colorectal cancer and in refractory metastatic gastric cancer (see section 4.2 for information on paediatric use).
Træthed, svimmelhed og utilpashed kan forekomme under behandlingen (se pkt.
Fatigue, dizziness or malaise may occur during treatment (see section 4.8).
De hyppigst observerede bivirkninger (≥ 30 %) hos patienter i behandling med Lonsurf er neutropeni (53 % [34 % ≥ grad 3]), kvalme (34 % [1 % ≥ grad 3]), træthed (32 % [4 % ≥ grad 3]), anæmi (32 % [12 % ≥ grad 3]).
The most frequently observed adverse drug reactions (≥ 30%) in patients receiving Lonsurf are neutropenia (53% [34% ≥ Grade 3]), nausea (34% [1% ≥ Grade 3]), fatigue (32% [4% ≥ Grade 3]), anaemia (32% [12% ≥ Grade 3]).
I de farmakokinetiske analyser efter multipel administrationen af Lonsurf (35 mg/m dagligt med 5 dages behandling og 2 dages pause i 2 uger, efterfulgt af 14 dages pause og gentaget hver 4. uge), var arealet under koncentration-tid-kurven fra tid 0 til den sidste målbare koncentration (AUC0-sidste) for trifluridin ca. 3 gange højere, og maksimumkoncentrationen (Cmax) var cirka 2 gange højere efter administration af multiple doser (dag 12 i cyklus 1) af Lonsurf end efter en enkelt dosis (dag 1 i cyklus 1).
In the pharmacokinetic (PK) analyses of the multiple dose administration of Lonsurf (35 mg/m2/dose, twice daily for 5 days a week with 2 days rest for 2 weeks followed by a 14-day rest, repeated every 4 weeks), trifluridine area under the concentration-time curve from time 0 to the last measurable concentration (AUC0-last) was approximately 3-fold higher and maximum concentration (Cmax) was approximately 2-fold higher after multiple dose administration (Day 12 of Cycle 1) of Lonsurf than after single-dose (Day 1 of Cycle 1).
Bidrag fra tipiracilhydrochlorid
Contribution of tipiracil hydrochloride
• højt blodsukker (hyperglykæmi), øget indhold af natrium, urinstof, kreatinin og kalium i blodet
• high blood sugar (hyperglycaemia), increased salt, urea, creatinine and potassium in your blood